Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

A Correction to this article was published on 31 March 2020

This article has been updated

Abstract

Purpose

Neoadjuvant chemotherapy (NAC) followed by esophagectomy has become a standard treatment for esophageal squamous cancer (ESCC) in Japan. We used propensity-matching analysis to clarify the safety and efficacy of NAC in daily clinical practice.

Methods

We reviewed the medical records of 335 patients with clinical Stage II/III ESCC diagnosed between 2007 and 2012, including 191 who received preoperative NAC (NAC group) and 144 treated by upfront surgery (US group). After propensity score matching, there were 118 patients in each group. We compared the postoperative complications and long-term outcomes between the groups.

Results

Seven patients in the NAC group underwent replacement therapy. Complications occurred in 76 (68.5%) and 76 (64.4%) patients in NAC and US groups, respectively (p = 0.51), and severe complications occurred in 17 (22.4%) and 30 (39.5%) patients, respectively (p = 0.057). One (0.8%) and three patients (2.5%) from the US group died within 30 days and 90 days after surgery, respectively, but none of the patients from the NAC group died within the same period. The 5-year survival rate was 54.9% in the NAC group and 41.2% in the US group (p = 0.024).

Conclusions

NAC is a safe and effective treatment to improve prognosis in the clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 31 March 2020

    In the original publication, in Abstract, the second sentence of Results has been incorrectly published as.

References

  1. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.

    Article  Google Scholar 

  2. Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.

    Article  Google Scholar 

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  Google Scholar 

  4. Coupland VH, Allum W, Blazeby JM, Mendall MA, Hardwick RH, Linklater KM, et al. Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer. 2012;12:11.

    Article  Google Scholar 

  5. Pandeya N, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol. 2013;37:579–84.

    Article  CAS  Google Scholar 

  6. Vioque J, Barber X, Bolumar F, Porta M, Santibanez M, de la Hera MG, et al. Esophageal cancer risk by type of alcohol drinking and smoking: a case–control study in Spain. BMC Cancer. 2008;8:221.

    Article  Google Scholar 

  7. Lee CH, Wu DC, Lee JM, Wu IC, Goan YG, Kao EL, et al. Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of the oesophagus in relation to tobacco smoking. Eur J Cancer. 2007;43(7):1188–99.

    Article  CAS  Google Scholar 

  8. Robert NJ, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, et al. HER2-positive metastatic breast cancer patients receiving Pertuzumab in a community oncology practice setting: treatment patterns and outcomes. Drugs Real World Outcomes. 2017;4:1–7.

    Article  Google Scholar 

  9. Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017;3:382–90.

    Article  Google Scholar 

  10. Klevebro F, Lindblad M, Johansson J, Lundell L, Nilsson M. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry. Br J Surg. 2016;103(13):1864–73.

    Article  CAS  Google Scholar 

  11. Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32:2416–22.

    Article  CAS  Google Scholar 

  12. Surgical resection with. or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–33.

    Article  Google Scholar 

  13. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  Google Scholar 

  14. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.

    Article  CAS  Google Scholar 

  15. Sobin LHMKG, Wittekind C. TNM classification of malignant tumours. 7th Edn. Hoboken:Wiley-Blackwell; 2011.

    Google Scholar 

  16. Japan Esophageal Society. Japanese classification of esophageal cancer. Part I esophagus. 11th edn, 2017;14:1–36.

  17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    Article  Google Scholar 

  18. Rubin PRRDB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–5.

    Article  Google Scholar 

  19. Kataoka K, Nakamura K, Mizusawa J, Fukuda H, Igaki H, Ozawa S, et al. Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. Br J Surg. 2015;102:1088–96.

    Article  CAS  Google Scholar 

  20. Kataoka K, Takeuchi H, Mizusawa J, Igaki H, Ogawa S, Abe T, et al. Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: exploratory analysis of JCOG9907. Ann Surg. 2017;265:1152–7.

    Article  Google Scholar 

  21. Yoshida N, Baba Y, Hiyoshi Y, Shigaki H, Kurashige J, Sakamoto Y, et al. Duration of smoking cessation and postoperative morbidity after esophagectomy for esophageal cancer: How long should patients stop smoking before surgery? World J Surg. 2016;40:142–7.

    Article  Google Scholar 

  22. Cerantola Y, Hubner M, Grass F, Demartines N, Schäfer M. Immunonutrition in gastrointestinal surgery. Br J Surg. 2011;98:37–48.

    Article  CAS  Google Scholar 

  23. Mabvuure NT, Roman A, Khan OA. Enteral immunonutrition versus standard enteral nutrition for patients undergoing oesophagogastric resection for cancer. Int J Surg. 2013;11:122–7.24.

    Article  Google Scholar 

  24. Engelman E, Maeyens C. Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy. J Gastrointest Surg. 2010;14(5):788–804.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Takanori Kurogochi, Michitaka Honda, Kotaro Yamashita, Masaru Hayami, Akihiko Okamura, Yu Imamura, Shinji Mine & Masayuki Watanabe

  2. Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan

    Michitaka Honda

Authors
  1. Takanori Kurogochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michitaka Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kotaro Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaru Hayami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihiko Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shinji Mine
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masayuki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Watanabe.

Ethics declarations

Conflict of interest

We have no conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurogochi, T., Honda, M., Yamashita, K. et al. Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma. Surg Today 49, 150–157 (2019). https://doi.org/10.1007/s00595-018-1718-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-018-1718-8

Keywords

Search

Navigation